Attempt to undermine European ban on advertising drugs fails in France

BMJ 2007; 334 doi: http://dx.doi.org/10.1136/bmj.39115.464931.DB (Published 8 February 2007)
Cite this as: BMJ 2007;334:279.1

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ray Moynihan
  1. 1Byron Bay, Australia

    A controversial proposal to have drug companies' “patient compliance” programmes declared legal in France has failed.

    Critics described the proposal as a backdoor attempt to introduce into France direct to consumer drug advertising, which is currently banned throughout Europe.

    Compliance support programmes organised by drug companies can include telephone reminders to consumers, personalised information for patients, and even home visits from nurses. The drug industry defends public health programmes as valuable for boosting adherence to treatment; others argue the programmes are Big Brother-style marketing strategies intended to boost profits.

    A recently formed advocacy group called the Medicines in Europe Forum, which comprises patients, professionals, and others, successfully …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL